Market Cap
$85.2M
ONCY
ONCOLYTICS BIOTECH INC
$0.6235 ▼ -2.58%
Prev close $0.6400Market cap$85.2M
ConsensusBuy
12-mo target$4.14 (+563.8%)
▲ Bullish
Analyst conviction 8/10
Insider Buying Cluster (2 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on ONCY right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (75%)
Inst. Holders
43 funds
Inst. Value
$2.0M
Insider Activity
$258.8K buy / $0.00 sell
Insider Net $
$258.8K
Social Sentiment
67° Warm
SEC Reports
14
Press Releases
1
Price chart 30d -29.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 other
Sep 10, 2026 SEC Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Oncolytics published data showing pelareorep’s potential to turn an inactive liver tumor microenviro
Oncolytics Biotech announced positive preclinical results combining its lead candidate pelareorep with a pan-RAS inhibit
8-K — Impact 4/10
Oncolytics Biotech announced FDA Fast Track Designation for pelareorep in combination with a checkpoint inhibitor for se
8-K — Impact 6/10
Oncolytics Biotech provided a clinical and regulatory update on its REO 033 study in RAS-mutant MSS colorectal cancer, r
8-K — Impact 4/10
Jun 1, 2026 Insider
Brown Deborah Margaret was granted 30,000 shares
Director
Jun 1, 2026 Insider
Andrews Patricia S was granted 30,000 shares
Director
Jun 1, 2026 Insider
May 22, 2026 Press Holtham Angela was granted 30,000 shares
Director
Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showi
Impact 4/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
75% rate it Buy or better · 8 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 1 | 5 | 2 | 0 | 0 | 75% |
Price targets
Where 6 covering analysts think ONCY trades over the next 12 months.
$4.14 +563.8% upside Strong Buy
Current$0.6235 Low$2.84 Median$4.14 High$5.84 6 analysts
$2.84$5.84
Analyst rating Buy· 1.8/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 6 bullish, 3 bearish, 0 mixed, 5 neutral · avg impact 5.0/10.Plus 1 press releases.
NEUTRAL8-K4/10
Oncolytics Biotech announced positive preclinical results combining its lead candidate pelareorep wi
Sep 10, 2026
BULLISH8-K6/10
Oncolytics Biotech announced FDA Fast Track Designation for pelareorep in combination with a checkpo
Jul 20, 2026
NEUTRAL8-K4/10
Oncolytics Biotech provided a clinical and regulatory update on its REO 033 study in RAS-mutant MSS
Jul 13, 2026
BULLISH8-K5/10
Oncolytics Biotech announced the USPTO issued a new patent protecting the commercial manufacturing p
Jun 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
other
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Oncolytics published data showing pelareorep’s potential to turn an inactive liver tumor microenvironment active and susceptible to immune therapy.
Sep 28, 2026
other
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Oncolytics announced continued clinical and operational progress for the REO 033 program evaluating pelareorep in second-line RAS-mutant mCRC.
Sep 11, 2026
short_volume
Short Volume: ONCY — 61.8% short (0.5M / 0.8M)
Short: 484,298 | Exempt: 50 | TRF Vol: 783,866 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
fda
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer mode
Aug 14, 2026
short_volume
Short Volume: ONCY — 56.3% short (0.4M / 0.8M)
Short: 444,322 | Exempt: 145 | TRF Vol: 789,643 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.08 | $-0.08–$-0.07 | 43.8% | -0.4% | 1↑ 0↓ | $0.0B | 3 |
| Next Q | $-0.09 | $-0.10–$-0.08 | — | -0.3% | 1↑ 1↓ | $0.0B | 4 |
| Current FY | $-0.38 | $-0.38–$-0.37 | 9.4% | -0.9% | 0↑ 2↓ | $0.0B | 2 |
| Next FY | $-0.28 | $-0.28–$-0.23 | 26.0% | -0.3% | 2↑ 0↓ | $0.0B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.079 | — |
| 7d ago | $-0.078 | -0.001 |
| 30d ago | $-0.078 | -0.000 |
| 60d ago | $-0.076 | -0.002 |
| 90d ago | $-0.076 | -0.003 |
Institutional ownership
Which big funds own ONCY (from quarterly 13F filings) and who is adding or trimming.
43 institutional holders with $2.0M total value (2,220,101 shares) as of 2026-Q2. Top holders: MARSHALL, GOLDMAN, SUSQUEHANNA.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MARSHALL WACE, LLP | 745,350 | $708.1K | 35.6% | — |
| GOLDMAN SACHS GROUP INC | 169,898 | $161.4K | 8.1% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 134,129 | $127.4K | 6.4% | — |
| Invesco Ltd. | 101,195 | $96.1K | 4.8% | — |
| LPL Financial LLC | 80,316 | $76.3K | 3.8% | — |
| FRANKLIN RESOURCES INC | 79,842 | $75.8K | 3.8% | — |
| CIBC WORLD MARKET INC. | 69,303 | $65.8K | 3.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 66,939 | $63.6K | 3.2% | — |
| RENAISSANCE TECHNOLOGIES LLC | 62,010 | $58.9K | 3.0% | — |
| ROYAL BANK OF CANADA | 57,411 | $55.0K | 2.8% | — |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 25 transactions. Net $258.8K — $258.8K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Brown Deborah Margaret | Director | AWARD | 30,000 | — | — |
| Jun 1, 2026 | Andrews Patricia S | Director | AWARD | 30,000 | — | — |
| Jun 1, 2026 | Holtham Angela | Director | AWARD | 30,000 | — | — |
| Jun 1, 2026 | Glover Stephen C. | Director | AWARD | 96,000 | — | — |
| Jun 1, 2026 | Heineman Thomas Charles | Chief Medical Officer | AWARD | 260,000 | — | — |
| Jun 1, 2026 | Seizinger Bernd R. | Director | AWARD | 30,000 | — | — |
| Jun 1, 2026 | Parsons James T. | Director | AWARD | 30,000 | — | — |
| Jun 1, 2026 | Hagerman Allison | Chief Technology Officer | AWARD | 260,000 | — | — |
| Jun 1, 2026 | McAdory John Bearden | Chief Operating Officer | AWARD | 145,000 | — | — |
| Jun 1, 2026 | Look Kirk | Chief Financial Officer | AWARD | 260,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ONCY.
Shares short
8,647,953
Settlement Sep 15, 2026
Change vs prior
+10.8%
Semi-monthly cycle
Days to cover
7.2
At avg daily volume
Of shares outstanding
≈6.8%
Estimate — not % of float
All ONCY filing & press-release reports (15)
- 8-K reportSep 10, 2026
- 8-K reportJul 20, 2026
- 8-K reportJul 13, 2026
- 8-K reportJun 16, 2026
- 8-K reportJun 2, 2026
- 8-K reportJun 1, 2026
- 8-K reportMay 22, 2026
- PRESS-RELEASE reportMay 22, 2026
- 8-K reportApr 27, 2026
- 424B5 reportApr 6, 2026
- 8-K reportApr 6, 2026
- EFFECT reportApr 6, 2026
- S-3 reportApr 1, 2026
- CLUSTER reportMar 13, 2026
- 8-K reportFeb 24, 2026